Skip to main content
OpenTrials
Completed

NCT Number: NCT05362357

iSTART: A Campus & Community Initiative for Services in Tec-health

The iSTART intervention is a 30-day substance prevention web-app whereby students complete five weekly interactive modules using a smart device or computer. Each module is approximately 15 minutes long, and focuses on a select substance: (i) alcohol, (ii) marijuana, (iii) nicotine, (iv) prescription drugs, and (v) illicit drugs. The modules are based on key theoretical constructs, behavior change strategies, and practical module components: attitudes (knowledge), perceived susceptibility (risk perceptions), subjective norms (normative re-education), and self-efficacy (refusal skills). This intervention will be evaluated via a time series design using a sample of 600 students randomly assigned to either the intervention, comparison, or control condition at a public institution in southern California.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

California State University, Northridge

Northridge, California, 91330, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current Cal State Northridge (CSUN) matriculated students
  • Age 18-30

Exclusion criteria

  • Not currently a CSUN student
  • Not 18-30 years of age
  • Identified as having an alcohol or substance use disorder (AUD or SUD) as determined by the brief DSM-5 screener

Treatment and study plan

iSTART Web-app

Behavioral

30-day substance prevention web-app for students at a Hispanic Serving Institution.

Primary outcomes

  1. Change from baseline alcohol use behavior at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured as the number of days drinking alcohol in past 30-days

  2. Change from baseline binge drinking at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured as the number of days consumed five or more alcoholic beverages at the same time for males; four or more for females in past 30-days.

  3. Change from baseline tobacco use at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured as the number of days using cigarettes, pipe tobacco, chewing tobacco, snus in past 30-days.

  4. Change from baseline electronic vaping at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured as the number of days vaped in past 30-days.

  5. Change from baseline marijuana use at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured as the number of days smoked marijuana in past 30-days.

  6. Change from baseline non-prescribed prescription drug use at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured as the number of days used stimulants, sedatives, benzodiazepines, and prescription opioids in past 30-days.

  7. Change from baseline illicit drug use at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured as the number of days used cocaine, amphetamines, MDMA/Ecstasy, heroin, fentanyl, and non-Rx opioids in past 30-days.

Secondary outcomes

  1. Change from baseline behavioral intent at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured as the intent to smoke marijuana/cigarettes, binge drink, and use non-prescribed drugs. Participants are asked to rate the likelihood of use in the next 30 days on a four-point Likert scale from 1=very likely to 4=very unlikely.

  2. Change from baseline alcohol-specific outcomes at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured as participants who report any past 30-day alcohol use indicate how many times they have experienced ten select outcomes in the last 30 days while drinking alcohol, or as the result of their alcohol use. Example items include: 'Not being able to do your homework or study for a test', 'Missed out on other things because you spent too much money on alcohol', 'Went to work or school high or drunk', 'Felt that you needed more alcohol than you used to use in order to get the same effect', and 'Had withdrawal symptoms, that is, felt sick because you stopped or cut down on drinking'. Participants respond: 'never', '1-2 times', '3-5 times', '6-10 times', and 'more than 10 times' in the past 30-days.

Other outcomes

  1. Change from baseline risk perceptions at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured by participants' evaluation of their perceived risk level for the following six substance use behaviors: binge drinking once or twice a week, tobacco use once or twice a week, marijuana use once or twice a week, prescription opioid use once or twice a week, non-prescription opioid use once or twice a week, sharing needles/injection equipment, injecting drugs, and illicit drug use. Response options for each behavior include 1='no risk', 2='slight risk', 3='moderate risk', 4='great risk', or 9='don't know'.

  2. Change from baseline subjective norms at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Measured by participants' indication of what percentage of students on campus they perceive use a variety of substances within the last 30 days, (i.e., alcohol, cigarettes, marijuana, different prescription drugs, and several illicit drugs) choosing one of ten percentile intervals from 0-100%.

  3. Change from baseline refusal self-efficacy at 3 months.

    Time frame: Baseline and 90-days following intervention completion.

    Self-efficacy will be evaluated through two refusal skills statements: "I would be able to say no if a friend offered me a drink of alcohol" and "I would be able to refuse if a friend offered me drugs, including marijuana", by indicating their level of agreement on a four-point Likert scale from 1='strongly agree' to 4='strongly disagree'.

  4. Socio-demographics

    Time frame: Baseline

    Participant characteristics, including age, Hispanic origin, race, sex at birth, gender identification, sexual orientation, living situation, college status, military service/veteran status, arrest history, parole/probation status, and household income

  5. Adverse Childhood Experiences (ACE)

    Time frame: Baseline

    ACE are conceptualized as maltreatment (e.g., verbal, emotional, physical, and sexual abuse), and household dysfunction (e.g., parent/caregiver substance use, intimate partner violence, incarceration, homelessness, mental illness, separation/divorce (71). Participants respond to each of the ten ACE items as 1=Yes or 0=No. An ACE score will be computed with a range from 0-10.

  6. Developmental transition

    Time frame: Baseline

    Participants respond 1=Yes or 0=No to a list of 18 major life events within the last three years. Example life events include: getting into a new romantic relationship; breaking up with a girlfriend or boyfriend; losing a job; being unemployed and not able to find work; caring for a parent or relative; getting extremely ill; having a baby; losing a baby; or having family separated due to immigration. A total score will be computed with a range from 0-18.

Sponsors and collaborators

Lead sponsor

California State University, Northridge

Other

Registry information

Acronym: iSTART

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
May 5, 2022
Registry last updated
Feb 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.